MedImpact Holdings Inc. is on the brink of introducing an unbranded ustekinumab-aekn biosimilar that will disrupt the specialty pharmacy market in the United States. This groundbreaking biosimilar will be available through any licensed specialty pharmacy, offering an incredible 95% discount compared to Stelara, starting January 1, 2026. Distributed by Anda, an affiliate of Teva Pharmaceuticals USA, this game-changing product is poised to revolutionize the industry.
With a steadfast commitment to price transparency and reducing reliance on rebates, MedImpact’s introduction of the ustekinumab-aekn biosimilar marks a significant step towards affordable healthcare. By bypassing the traditional supply chain costs, this biosimilar promises substantial savings for pharmacies, payers, and most importantly, patients. Arpit Patel, MedImpact’s Senior Vice President of Trade Relations and Supply Chain, emphasizes the company’s dedication to ensuring accessibility without compromising on affordability.
The exorbitant costs of biologic therapies have long hindered patients from accessing essential treatments for immune-mediated inflammatory conditions. Despite accounting for only 2% of all prescriptions, biologic drugs contribute to a staggering 46% of drug spending in the U.S. Biosimilars offer a ray of hope, as they cost approximately 50% less than their biologic counterparts. Projections indicate that the adoption of biosimilars could result in savings of up to $181 billion over the next five years, providing a lifeline for millions of Americans battling chronic conditions.
Stelara, the reference product for ustekinumab, has been a cornerstone in the treatment of various immune-inflammatory conditions since its FDA approval in 2009. With eight biosimilars covering multiple indications for both adult and pediatric patients, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, Stelara has established itself as a trusted therapy. However, the prohibitive price tag of $25,497.12 every eight weeks has limited its accessibility, especially for patients reliant on government-funded programs.
The impending availability of the ustekinumab-aekn biosimilar is a beacon of hope for patients seeking affordable treatment options. As the patents for Stelara expired in 2023, paving the way for a wave of biosimilars, the market is witnessing a transformation that prioritizes cost-effectiveness without compromising on quality. Imuldosa’s recent announcement of prefilled syringes at a 92% discount and vial formulations at a 30% discount further underscores the growing trend towards accessible healthcare solutions.
In conclusion, the introduction of the unbranded ustekinumab-aekn biosimilar by MedImpact heralds a new era of affordability and accessibility in specialty pharmacy. With substantial cost savings, enhanced price transparency, and a commitment to delivering value to all stakeholders, this biosimilar is poised to make a profound impact on patients’ lives. As the healthcare landscape evolves towards a more sustainable future, biosimilars stand out as a beacon of hope for those in need of life-changing treatments. Embrace the future of healthcare with MedImpact’s ustekinumab-aekn biosimilar and join the movement towards affordable, high-quality care.
- Biosimilars offer a 50% cost reduction compared to biologics, potentially saving $181 billion in the next five years.
- The ustekinumab-aekn biosimilar will be available at a 95% discount from Stelara, enhancing affordability and accessibility.
- MedImpact’s commitment to price transparency and value delivery promises a paradigm shift in the specialty pharmacy landscape.
- Patients facing immune-inflammatory conditions can now access life-changing therapies without compromising on quality or affordability.
Tags: formulation, biosimilars
Read more on managedhealthcareexecutive.com